Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse-Reference-Cited by-同舟云学术

Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse

Published:2020-01-02 Issue:6 Volume:188 Page:907-917
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Montefusco Vittorio¹^ORCID,Corso Alessandro²,Galli Monica³,Ardoino Ilaria⁴,Pezzatti Sara⁵,Carniti Cristina¹^ORCID,Patriarca Francesca⁶^ORCID,Gherlinzoni Filippo⁷,Zambello Renato⁸,Sammassimo Simona⁹,Marcatti Magda¹⁰,Nozza Andrea¹¹,Crippa Claudia¹²,Cafro Anna Maria¹³,Baldini Luca¹⁴,Corradini Paolo¹¹⁵

Affiliation:

1. Hematology Fondazione IRCCS Istituto Nazionale dei Tumori MilanItaly

2. Division of Hematology Fondazione IRCCS Policlinico San Matteo Università di Pavia PaviaItaly

3. Hematology Papa Giovanni XXIII hospital BergamoItaly

4. Istituto di Ricerche Farmacologiche “Mario Negri” – IRCCS MilanItaly

5. Hematology San Gerardo hospital MonzaItaly

6. DISM University of Udine UdineItaly

7. Hematology Ca’ Foncello hospital TrevisoItaly

8. Department of Medicine, Hematology and Clinical Immunology Branch Padua University School of Medicine PaduaItaly

9. Hematoncology European Institute of Oncology Milan Italy

10. Hematology and Bone Marrow Transplantation Unit IRCCS San Raffaele Scientific Institute MilanItaly

11. Oncology and Hematology Department Istituto Clinico Humanitas, Rozzano (MI) MilanItaly

12. Hematology Spedali Civili di Brescia BresciaItaly

13. Department of Oncology/Hematology Niguarda Ca' Granda Hospital MilanItaly

14. Hematology/Bone Marrow Transplantation Unit Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico Ca'Granda Ospedale Maggiore PoliclinicoUniversity of Milan MilanItaly

15. Department of Oncology and Hematology University of Milan Milan Italy

Funder

Associazione Italiana per la Ricerca sul Cancro

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.16287

Reference28 articles.

1. Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma

2. Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma